How should healthcare teams evaluate LLM summaries of real-world evidence before using them in clinical workflows?

Why This Matters for Security Teams

LLM-generated summaries of real-world evidence can be useful as a triage aid, but in clinical workflows they are not a substitute for evidence appraisal. The risk is not only missing context, but also subtle distortion: a summary can preserve the right study title while reversing the direction of effect, flattening uncertainty, or dropping inclusion criteria that materially change how findings should be interpreted. That is why evaluation should be tied to the source evidence, not to whether the prose sounds plausible.

For healthcare organisations, this is a patient safety and governance issue. A summary that overstates benefit or understates harm can influence treatment pathways, formulary decisions, and protocol updates. Current guidance suggests treating these outputs as assisted drafting artefacts that require verification, traceability, and documented review, consistent with the NIST AI Risk Management Framework. In practice, teams often discover the problem only after an apparently polished summary has already been folded into a clinical discussion, rather than through a deliberate validation step.

How It Works in Practice

The most reliable evaluation approach is to compare each LLM summary against the exact evidence object it claims to represent, such as the paper, abstract, table, endpoint analysis, or systematic review section. For real-world evidence, that means checking whether the model keeps the same population, comparator, timeframe, outcome definitions, and limitations. A summary can be fluent and still be clinically unsafe if it merges different endpoints, cites the wrong cohort, or converts exploratory findings into causal language.

A practical review process usually includes:

• Confirming the source and version of the evidence being summarised.
• Checking numeric fidelity for effect sizes, confidence intervals, event counts, and direction of effect.
• Verifying that limitations, confounders, and uncertainty are not omitted.
• Testing whether the summary preserves distinction between association and causation.
• Recording a human approval step before any clinical use.

Healthcare teams should also align the review process with AI governance expectations in the NIST AI 600-1 Generative AI Profile, especially where the model is used to draft evidence synopses for decision support. If the workflow includes retrieval, source ranking, or automated citation insertion, agentic risks such as tool misuse, prompt injection, and unsupported chaining become relevant, which is why the OWASP Agentic AI Top 10 is a useful reference point. These controls tend to break down when the summary is generated from mixed-source repositories with inconsistent metadata because the model cannot reliably preserve study boundaries.

Common Variations and Edge Cases

Tighter review often increases time pressure on clinical and research staff, requiring organisations to balance speed against evidentiary integrity. That tradeoff becomes sharper when teams want summaries for rapid literature surveillance, protocol meetings, or early signal detection. Best practice is evolving here: there is no universal standard for acceptable error thresholds in LLM summaries of RWE, so organisations should define their own tolerance based on clinical risk and intended use.

Edge cases include summaries of observational studies with confounding by indication, mixed-quality evidence packs, and outputs that blend peer-reviewed research with registry data or preprints. In those settings, even a technically accurate summary can mislead if it fails to state that the evidence is low certainty or hypothesis-generating. Teams should also be cautious when the model compresses multiple studies into a single narrative, because disagreement across studies can disappear in the process.

Where agentic workflows generate the summary and then route it into downstream systems, the review should include provenance checks and output validation, not just language quality. The MITRE ATLAS adversarial AI threat matrix is helpful for thinking about manipulation and integrity risks, even in clinical environments, while the CSA MAESTRO agentic AI threat modeling framework can help teams structure controls around autonomy and tool use. The guidance breaks down most often when summaries are reused across departments without local clinical review, because context-specific meaning is lost.

Related resources from NHI Mgmt Group

• How should teams evaluate AI coding tools before using them in production?
• What should security teams check before using chat to build provisioning workflows?
• How should healthcare teams reduce password reset tickets without disrupting clinical workflows?
• What should security teams evaluate before using compound AI systems in production?